The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.
Common Adverse Events With Second- and Third-Line Therapies in Patients With HER2+ mBC
November 16th 2023Joseph Gligorov, MD, discusses the potential side effects of second- and third-line therapies for patients with HER2+ metastatic breast cancer and highlights the low-toxicity profile of tucatinib when combined with trastuzumab and capecitabine.
Watch
Dr Conlin on Targeting CNS Metastases in the Treatment of Breast Cancer
November 15th 2023Alison K. Conlin, MD, discusses the importance of targeting central nervous system metastases in the treatment of patients with breast cancer, highlighting ongoing treatment investigations for this population.
Watch
Dr Modi on Updated OS Data From the DESTINY-Breast04 Trial of T-DXd in HER2-Low Breast Cancer
November 15th 2023Shanu Modi, MD, discusses updated survival data from the phase 3 DESTINY-Breast04 trial evaluating fam-trastuzumab deruxtecan-nxki in patients with HER2-low metastatic breast cancer.
Watch
In this second episode of OncChats: Reviewing Best Practices in the Surgical Management of Breast Cancer, Gladys Giron, MD, FACS, and Cristina Lopez-Peñalver, MD, discuss the traditional surgical approaches that are utilized for patients with breast cancer and some of the challenges faced in those with later-stage disease.
Watch
Dr Haffty on Technical and Biological Advancements in Radiotherapy Within Breast Cancer
November 12th 2023Bruce Haffty, MD, MS, discusses the significance of technical and biological advancements in approaches to radiotherapy, and how they engendered the de-escalation of radiotherapy for select patients with breast cancer.
Watch
Multimodal Care Marks the Past, Present, and Future of Localized Breast Cancer Management
November 10th 2023Improvements in screening, systemic therapy, and precision medicine have reduced breast cancer mortality and morbidity, and further progress will hinge on the use of ctDNA and CTCs for disease monitoring, continued development of novel antiestrogenic agents, and movement of ADCs and immunotherapy into expanded settings and indications.
Read More
Dr Jhaveri on the Evolution of Endocrine Therapy in ER+ Metastatic Breast Cancer
November 10th 2023Komal Jhaveri , MD, FACP, discusses the rationale behind the ongoing clinical development of elacestrant and other endocrine therapies in patients with estrogen receptor–positive metastatic breast cancer.
Watch
TROP2-Targeting Antibody-Drug Conjugates
The expert panel discusses TROP2 as a target for patients with cancer who are receiving antibody-drug conjugates.
Watch
Approved Antibody-Drug Conjugates in Breast, Lung, and GI Malignancies
A review of antibody-drug conjugates approved for treatment of patients with breast, lung, or gastrointestinal cancers.
Watch
French Clinical Data and Real-World Evidence on Treatment Sequencing for HER2+ mBC
November 9th 2023Dr Gligorov underscores the significance of real-world data in France supporting the effectiveness of tucatinib and trastuzumab in combination for patients with heavily pretreated HER2+ metastatic breast cancer, with notable benefits even in cases with brain metastasis.
Watch
Treatment Sequencing Approaches for Patients With HER2+ mBC
November 9th 2023Joseph Gligorov, MD, recommends using tucatinib in combination with trastuzumab and capecitabine as a preferred strategy after trastuzumab deruxtecan, favoring it over another antibody-drug conjugate (ADC) due to limited data on the latter's effectiveness.
Watch
Monitoring Patients With HER2+ mBC After Discontinuing Trastuzumab Deruxtecan
November 3rd 2023Jane Meisel, MD, delves into considerations around discontinuing trastuzumab deruxtecan for the treatment of HER2+ metastatic breast cancer, explaining that therapy may be halted due to disease progression or toxicity, and the importance of monitoring patients with regular scans.
Watch
Managing T-DXd Toxicities in Gastric Cancer
Insights on managing antibody-drug conjugate toxicities for patients with gastric cancer.
Watch
Gastric Cancer Treatment: T-DXd
A GI medical oncologist discusses the role of trastuzumab deruxtecan in the gastric cancer treatment space.
Watch
Trastuzumab Deruxtecan for Patients With HER2+ Metastatic Breast Cancer (mBC)
November 2nd 2023Dr Joseph Gligorov highlights the impact of trastuzumab deruxtecan in treating HER2-positive breast cancer due to its impressive results in progression-free survival and overall survival, emphasizing its importance in early treatment, while acknowledging the need to monitor safety issues.
Watch
MRD and ctDNA Could Shift into Larger Role to Guide Treatment Decisions in Breast Cancer
October 27th 2023Praveen Vikas, MBBS, discusses what is currently known regarding minimal residual disease testing in breast cancer, expanded on what still needs to be done to bring minimal residual disease and ctDNA testing to clinical practice, and highlighted the evolving treatment paradigm for patients with advanced hormone receptor-positive, HER2-negative breast cancer.
Read More